Susquehanna downgrades Simcere Pharmeceutical Group (NYSE: SCR) from Positive to Neutral with reduced revenue expectation below the Street for FY10-FY12.

According ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE